Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SWTX SpringWorks Therapeutics	$46.21 +0.1%	$44.60	$28.21 ▼ $62.00	$3.46B	0.77	1.96 million shs	7.57 million shs
VKTX Viking Therapeutics	$27.57 +2.1%	$26.15	$18.92 ▼ $81.81	$3.10B	0.75	4.09 million shs	3.39 million shs
ZLAB Zai Lab	$28.36 -3.5%	$32.90	$16.01 ▼ $39.77	$3.13B	1.04	863,546 shs	1.03 million shs
ZYME Zymeworks	$11.33 -3.5%	$11.91	$8.21 ▼ $17.70	$788.31M	1.24	604,741 shs	462,652 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SWTX SpringWorks Therapeutics	+0.10%	-0.21%	+24.91%	+17.63%	+0.99%
VKTX Viking Therapeutics	+2.09%	-4.49%	+29.58%	-12.35%	-65.36%
ZLAB Zai Lab	-3.47%	-10.51%	-1.56%	+1.98%	+70.02%
ZYME Zymeworks	-3.49%	-12.91%	+8.63%	-24.01%	+24.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SWTX SpringWorks Therapeutics	1.8969 of 5 stars	3.1	3.0	0.0	2.5	0.8	0.6
VKTX Viking Therapeutics	4.5818 of 5 stars	4.5	2.0	4.7	3.3	3.3	0.0
ZLAB Zai Lab	2.3807 of 5 stars	3.4	1.0	0.0	3.6	2.5	0.6
ZYME Zymeworks	2.6674 of 5 stars	3.4	0.0	0.0	3.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	13.78% Upside
VKTX Viking Therapeutics	3.00	Buy	$87.15	216.07% Upside
ZLAB Zai Lab	2.75	Moderate Buy	$47.37	67.02% Upside
ZYME Zymeworks	2.88	Moderate Buy	$21.00	85.35% Upside

Current Analyst Ratings Breakdown

Latest ZYME, SWTX, ZLAB, and VKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00
4/29/2025	SWTX SpringWorks Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
4/29/2025	SWTX SpringWorks Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$66.00 ➝ $47.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$77.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	SWTX SpringWorks Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$63.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$81.00 ➝ $47.00
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00

(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SWTX SpringWorks Therapeutics	$191.59M	18.08	N/A	N/A	$10.01 per share	4.62
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$3.48 per share	N/A
ZLAB Zai Lab	$398.99M	7.84	N/A	N/A	$8.05 per share	3.52
ZYME Zymeworks	$76.30M	10.33	N/A	N/A	$6.63 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SWTX SpringWorks Therapeutics	-$325.10M	-$3.48	N/A	N/A	N/A	-134.73%	-46.74%	-41.12%	N/A
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-11.93%	-11.57%	7/23/2025 (Estimated)
ZLAB Zai Lab	-$334.62M	-$2.59	N/A	N/A	N/A	-76.14%	-36.97%	-27.10%	5/8/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$1.61	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	5/8/2025 (Estimated)

Latest ZYME, SWTX, ZLAB, and VKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.33	-$0.45	-$0.12	-$0.45	$118.40 million	N/A
5/8/2025	N/A	ZYME Zymeworks	-$0.45	N/A	N/A	N/A	$20.65 million	N/A
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A
2/27/2025	Q4 2024	ZLAB Zai Lab	-$0.61	-$0.80	-$0.19	-$0.80	$110.15 million	$109.07 million
2/20/2025	Q4 2024	SWTX SpringWorks Therapeutics	-$0.66	-$1.04	-$0.38	-$1.04	$60.53 million	$61.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SWTX SpringWorks Therapeutics	N/A	6.16	6.02
VKTX Viking Therapeutics	N/A	36.47	36.47
ZLAB Zai Lab	N/A	3.01	2.87
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
SWTX SpringWorks Therapeutics	N/A
VKTX Viking Therapeutics	76.03%
ZLAB Zai Lab	41.65%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
SWTX SpringWorks Therapeutics	7.83%
VKTX Viking Therapeutics	4.10%
ZLAB Zai Lab	13.88%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
SWTX SpringWorks Therapeutics	230	74.98 million	68.73 million	Optionable
VKTX Viking Therapeutics	20	112.31 million	106.20 million	Optionable
ZLAB Zai Lab	1,950	110.33 million	94.24 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

ZYME, SWTX, ZLAB, and VKTX Headlines

Recent News About These Companies

Blackstone Inc. Has $8.34 Million Stock Position in Zymeworks Inc. (NYSE:ZYME)

May 8 at 6:09 AM | marketbeat.com

Raymond James Financial Inc. Takes $888,000 Position in Zymeworks Inc. (NYSE:ZYME)

May 8 at 3:27 AM | marketbeat.com

Jazz Pharmaceuticals Stock Price, Quotes and Forecasts

May 7 at 5:37 PM | benzinga.com

Zymeworks Inc. (NYSE:ZYME) Shares Sold by BVF Inc. IL

May 6 at 7:30 AM | marketbeat.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

May 6 at 1:17 AM | americanbankingnews.com

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from Brokerages

May 5 at 1:35 AM | americanbankingnews.com

Acuta Capital Partners LLC Acquires Shares of 67,240 Zymeworks Inc. (NYSE:ZYME)

May 4, 2025 | marketbeat.com

Invesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME)

May 4, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of "Moderate Buy" by Analysts

May 4, 2025 | marketbeat.com

Q2 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

May 3, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Purchases New Shares in Zymeworks Inc. (NYSE:ZYME)

May 3, 2025 | marketbeat.com

Zymeworks (ZYME) Expected to Announce Earnings on Thursday

May 3, 2025 | marketbeat.com

Leerink Partnrs Estimates Zymeworks' Q2 Earnings (NYSE:ZYME)

May 2, 2025 | americanbankingnews.com

Barclays PLC Has $3.23 Million Holdings in Zymeworks Inc. (NYSE:ZYME)

April 30, 2025 | marketbeat.com

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

April 28, 2025 | seekingalpha.com

Zymeworks: Poised For Growth With Platform Validation

April 28, 2025 | seekingalpha.com

JPMorgan Chase & Co. Grows Stake in Zymeworks Inc. (NYSE:ZYME)

April 28, 2025 | marketbeat.com

Zymeworks Inc.: Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

April 26, 2025 | finanznachrichten.de

Zymeworks Inc. Presents Promising Preclinical Data on Antibody-Drug Conjugates and T Cell Engagers at AACR Annual Meeting 2025

April 25, 2025 | quiverquant.com

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Jump Financial LLC Makes New Investment in Zymeworks Inc. (NYSE:ZYME)

April 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Are Tariffs Threatening Disney’s Comeback Story?
By Jea Yu | April 9, 2025
View Are Tariffs Threatening Disney’s Comeback Story?
Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Viking Therapeutics Stock Pops But Struggles to Hold Gains
By Chris Markoch | April 16, 2025
View Viking Therapeutics Stock Pops But Struggles to Hold Gains
Viking Therapeutics Stock May Struggle After As-Expected Report
By Chris Markoch | April 25, 2025
View Viking Therapeutics Stock May Struggle After As-Expected Report

ZYME, SWTX, ZLAB, and VKTX Company Descriptions

SpringWorks Therapeutics NASDAQ:SWTX

$46.20 +0.05 (+0.10%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$46.20 0.00 (0.00%)

As of 09:25 AM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Viking Therapeutics NASDAQ:VKTX

$27.57 +0.56 (+2.09%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$27.42 -0.16 (-0.56%)

As of 09:25 AM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Zai Lab NASDAQ:ZLAB

$28.36 -1.02 (-3.47%)

Closing price 05/7/2025 04:00 PM Eastern

Extended Trading

$28.61 +0.25 (+0.88%)

As of 09:21 AM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Zymeworks NYSE:ZYME

$11.33 -0.41 (-3.49%)

Closing price 05/7/2025 03:59 PM Eastern

Extended Trading

$12.12 +0.80 (+7.02%)

As of 04:43 AM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time